APAC Community Call

June 19, 2025

Agenda

- OHDSI Global/APAC News
- APAC Regional Mid-year Updates

OHDSI Global News

ATLAS user survey on
Data Sources and Vocabulary
is due by July 16

Do you use ATLAS to explore your datasets using your ACHILLES results in the Data Sources tab?

Do you use ATLAS to explore the OHDSI standardized vocabularies?

Share your experience with the community to support the development activities for the ATLAS V3 roadmap!



OHDSI Global News

ATLAS user survey on
ConceptSets and Cohort Definitions
is due by July 23

Conceptsets and Cohort Definitions are two of the most important and commonly used features within ATLAS Platform.

Development team would like to know the needs of the community about those two features!



OHDSI APAC News

🚀 2025 APAC Studies General Meeting

bi-weekly scheduled

MS Teams channels for each of three studies has been created.

👉 [2025 APAC Study - Fudan]

👉 [2025 APAC Study - Peking]

👉 [2025 APAC Study - USTC]

Warmly welcome your participation and contribution in each channel!



OHDSI APAC News

Next Meetings:

Fudan University: Tuesday, June 17

Peking University: Wednesday, June 18

USTC: Friday, June 20

🕘 All meetings begin at 9:00 am China Standard Time



2025 Mid-year Update

From OHDSI APAC

Photo by Anatoliy Gleb: https://www.shutterstock.com/g/anatoliy_gleb

APAC Regional Mid-year Updates

#	Regional Chapter	Name
1	Singapore	Evelyn Goh
2	Taiwan	Jason Hsu
3	Japan	Keiko Asao
4	India	Swetha Jakkuva
5	Thailand	Max Natthawut Adulyanukosol
6	Korea	Seng Chan You
7	Vietnam	Phan Thành Phúc
8	Malaysia	Steven Yong
9	China	Hui Lu

Presentations will proceed in the order the slide decks were received.

OHDSI June 2025 Updates

Singapore Chapter

Evelyn Goh

PhD Student

Assoc Prof. Mengling 'Mornin' Feng

Director of AI for Public Health

Saw Swee Hock School of Public Health

National University of Singapore

Use of GLP-1 receptor agonists and subsequent risk of acute liver injury

- GLP-1 receptor agonists (GLP-1 RA) increasingly used as treatment for T2DM (and obesity)
- Several case reports have arisen on acute liver injury (ALI) post-GLP-1 RA

Objective: Evaluate risk of ALI in T2DM users of GLP-1 RA

- In patients with T2DM, what are the **risks of ALI incidence** when prescribed with second-line GLP-1 RA compared to other classes of diabetes prescriptions?

Current status

- Wrote/executed one version of code with primary outcome
  - Executed R package across 14 cohorts – 9 cohorts included, primarily from US and Japan
  - No evidence of acute liver injury in those taking GLP1 (compared to DPP4i) !

- Adding new comparators and secondary outcomes to validate
  - New comparators: SGLT2i
  - Secondary outcomes: cholelithiasis, cholecystitis, lab-based values

Recruitment of data partners

- If you have a database, please participate in our study!
  - We especially need **more Asian cohorts**

- Contact Evelyn at e0983111@u.nus.edu

Plans for 2025

- Profession Certificates for OHDSI Training Course
  - In-principal approval by Dean
  - Plan to launch in Aug
  - Exploring potential collaborations with Australia and Taiwan Chapter
    - Keen to collaborate with the other chapters too
- New Master for Modeling, AI and Data Science for Public Health (M.MAD4PH)
  - Our new OHDSI course is one of the mandatory courses

Plans for 2025

- Continue to Support SG national initiatives

- Lead and participate in more APAC and Legend studies
  - GLP1 study
  - And many more
  - ….

- Help in the next APAC symposium in China

Regional Update



Jason C. Hsu

Taipei Medical University, Taiwan

June 19, 2025

Members in OHDSI Taiwan Society Office



Jason C. Hsu

Marc Hsu

Alex PA. Nguyen

Grace Huang

Alice Chen

Hsiu Chin Hu

Phan Thanh Phuc

Yudha E. Saputra

Whitney Burton

Septi Melisa

Christianus

Maz Solie



Natalie

Daniel Chris

Gusbela

Kian

David

Thomas

Carrie

Sunny

OHDSI Taiwan Society Members

臺北醫學大學 TAIPEI MEDICAL UNIVERSITY

臺北醫學大學附設醫院 TAIPEI MEDICAL UNIVERSITY HOSPITAL

衛生福利部雙和醫院 (委託臺北醫學大學興建經營) Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare

臺北市立萬芳醫院 TAIPEI MUNCIPAL WAN FANG HOSPITAL

台大醫院 NTUH

臺北榮民總醫院 Taipei Vete

三軍總醫院 Tri-Service General Hospital

林口長庚紀念醫院 Chang Gung Memorial Hospital, Linkou

天主教靈醫會醫療財團法人羅東聖母醫院 Camillian Saint Mary's Hospital Luodong

OHDSI TAIWAN

基隆長庚紀念醫院 Chang Gung Memorial Hospital, Keelung

國家衛生研究院 National Health Research Institutes

童綜合醫療社團法人童綜合醫院 Tungs' Taichung MetroHarbor Hospital

戴德森醫療財團法人嘉義基督教醫 CHIA-YI CHRISTIAN HOSPI

嘉義長庚紀念醫院 Chang Gung Memorial Hospital, Chiayi

奇美醫療財團法人奇美醫院 Chi Mei Medical Center

Pfizer

AstraZeneca

BAYER

NOVARTIS

Roche

MediPlug

An Automated conversion technology for common data models in Taiwan



Patent
(2024.12)

中華民國專利證書

發明第 I867630 號

發明名稱：資料協調的裝置及方法

專利權人：臺北醫學大學

發明人：許明暉、陳震宇、徐之昇、阮 建英、穆塔爾 穆罕默德索利胡丁、黃芝瑋

專利權期間：自2024年12月21日至2043年 7 月21日止

上開發明業經專利權人依專利法之規定取得專利權

經濟部智慧財產局 局長 廖承威

中華民國 113 年 12 月 21 日

Research Contributions

Taiwanese Teams Are Producing Globally Recognized RWE

Articles

eClinicalMedicine
(IF=9.6; Ranking=3%)

Risk of aortic aneurysm or dissection following use of fluoroquinolones: a retrospective multinational network cohort study

Jack L. Janetzki,[a,t] Jung Ho Kim,[b,t] Evan Minty,[c] Jung Ah Lee,[b] Daniel R. Morales,[d] Rohan
Scott L. DuVall,[g] Michael E. Matheny,[h] Thomas Falconer,[i] Seonji Kim,[j] Thanh-Phuc Phan,
Rae Woong Park,[n] Kenneth K. C. Man,[o] Sarah Seager,[p] Mui Van Zandt,[p] James P. Gilbert,[q]
George Hripcsak,[i] Nicole Pratt,[a,u] and Seng Chan You[j,u,*]

[a]Clinical and Health Sciences, Quality Use of Medicines and Pharmacy Research Cer
[b]Department of Internal Medicine, Yonsei University College of Medicine, Seoul,
[c]Department of Medicine, University of Calgary, Calgary, Canada
[d]Division of Population Health and Genomics, University of Dundee, Dundee, Ur
[e]Section of Cardiovascular Medicine, Department of Internal Medicine, Yale Univ
[f]Department of Clinical Pharmacy, Pharmacy Practice Research Unit, Faculty of P
[g]VA Informatics and Computing Infrastructure, United States Department of Vet
[h]Tennessee Valley Healthcare System, Veterans Affairs Medical Center, Nashville,
[i]Department of Biomedical Informatics, Columbia University, New York, USA
[j]Department of Biomedical Systems Informatics, Yonsei University College of Me
[k]International Ph.D. Program in Biotech and Healthcare Management, College of
City, Taiwan
[l]Clinical Data Center, Office of Data Science, Taipei Medical University, New Taipei City, Taiwan



Promote OHDSI's Value

- Data Policy Leadership
- NHI Optimization
- Regulatory Science
- Global Visibility



- Collaborative Teaching
- Global Projects
- Collaborative Research
- RWE Publications

- Faster RWE Generation
- Lifecycle Strategy
- International Federated Analytics

- Data Standardization
- AI Enablement
- Clinical Research
- Operational Benchmarking

Promote OHDSI at Government
(the Center for Drug Evaluation in Taiwan)

The CDE is a semi-official organization under the Taiwan Food and Drug Administration (TFDA).

財團法人醫藥品查驗中心
Center For Drug Evaluation

Promote OHDSI at Industry

TMU x Bayer Academia-Industry Collaboration Milestone Celebration

Promote OHDSI at Hospital

Professor Jason C. Hsu Appointed as Committee Member of Wanfang Hospital's Smart Healthcare Promotion Committee

臺北市立萬芳醫院
Taipei Municipal Wanfang Hospital

Welcome to join MedInfo 2025 in Taiwan!

If you plan to join it, please contact Jason (jasonhsu@tmu.edu.tw)

Thanks for your listening!

OHDSI Taiwan Society's Official Website: https://ohdsi-taiwan.com/

OHDSI Japan: 2025-1H Update

June 19, 2025

Activities & Achievements

JAPAC Symposium, Singapore, Dec. 2024



ATLAS Training, Tokyo, Feb. 2025

The Book of OHDSI in Japanese, Apr. 2025

Ongoing OMOP Conversion

- Esophageal cancer dataset, Kyoto Univ.
- And a few others

Publications and Presentations

- Kimura, E., Kawakami, Y., Inoue, S., & Okajima, A. (2024). Mapping Drug Terms via Integration of a Retrieval-Augmented Generation Algorithm with a Large Language Model. Healthcare Informatics Research, 30(4), 355–363. https://doi.org/10.4258/hir.2024.30.4.355
- Kimura, E., Kawakami, Y., Inoue, S., & Okajima, A. (2025). A dataset for mapping the Japanese drugs to RxNorm standard concepts. *Data in Brief*, *59*, 111418. https://doi.org/10.1016/j.dib.2025.111418
- Aoyagi, Y., Terao, S., Masahiro, B., Nomura, K., Ikeda, Y., & Sato, A. (2025). *Feasibility of converting Japanese oncology electronic medical records into the Observational Medical Outcomes Partnership Common Data Model and data quality assessment* (p. 2025.06.13.25329609). medRxiv. https://doi.org/10.1101/2025.06.13.25329609
- Aoyagi, Y, et al. Feasibility of Converting EMR Data to OMOP CDM and Utilizing OHDSI Analysis Tools in Japan. MedInfo2025.

Monthly Evening Conference

- General agenda
  - Journal Watch on OHDSI-related publications
  - Sharing OHDSI global/APAC topics and discussions
  - Topic of the month
    - January 27 Vocabulary mapping using LLM (Dr. E. Kimura)
    - February 28 Experiences using OMOP CDM (Dr. S. Okami)
    - March 28 The Book of OHDSI in Japanese (Drs. S. Matsumoto & K. Asao)
    - April 25 Progress of OHDSI Studies at the National Cancer Center Hospital East (Dr. Y. Aoyagi)
    - May 30 OMOP conversion of public databases (Dr. Yamashita)

FedAna Association (FedAna.jp)

- Est. March 2023, to promote the use of medical data and contribute to society, especially through federated data from multiple sites and OMOP CDM standardization

- Activities
  - ATLAS Training
  - OMOP Vocabulary Mapping Local Consensus Development

INDIA

OHDSI

OBSERVATIONAL HEALTH DATA SCIENCES AND INFORMATICS

OHDSI India Chapter

From Raw Data to Reliable Evidence

GLOBAL VALUE WEB

JSS ACADEMY OF HIGHER EDUCATION & RESEARCH (DEEMED TO BE UNIVERSITY) MYSURU

Version No: 1.0, Date: 19Jun2025

| © Copyright OHDSI India Chapter

Agenda

- OHDSI India – Current Landscape
- Updates on breast cancer study
- OHDSI India's Strategic Expansion: Aligning with FHIR & ABDM
- Vision 2026: Scaling OHDSI India's Impact

OHDSI India – Current Landscape

New collaborations

HEALTH PARLIAMENT
REAL WORK | GREAT LEADERS | RIGHT POLICIES

I-AIM

Academy of Clinical Translational Medicine

ASHOKA UNIVERSITY

Initiatives 2025

- Breast cancer study – Dr.Vikram
- Pediatric immunology study – Dr.Sagar
- Digital health in India – COE Rintu Kutum

Collaborators - 165 | Studies - 2 | Publication – 1 | CVD Registry - 1 | Training Session - 50 Reg

Please note that our OHDSI India Community Call is scheduled on the 3rd Thursday of every month.

Automated Extraction of Clinical Insights from Breast Cancer Discharge summaries Using NLP



OHDSI India's Strategic Expansion: Aligning with FHIR & ABDM

Strategic Objective
Align OHDSI India's data infrastructure with ABDM (Ayushman Bharat Digital Mission) FHIR standards

Underlying Opportunities
ABDM unlocks access to national health programs and platforms
Enables data monetization, registry licensing, EHR integration
Boosts pharma, med-tech, and health tech collaboration potential
Positions GVW for grants and digital health leadership

Action plan
Develop proof-of-concept linking OMOP CDM with FHIR APIs
Explore collaborations, partnerships and funding opportunities for further development

Vision 2026: Scaling OHDSI India's Impact

Strategic Objectives

Objective 1 - Establish OHDSI India as a national-level thought leader in real-world evidence & health data research

Objective 2 - Expand collaboration with 10+ hospitals, 5+ universities, 5+ pharma and target public health partners

Objective 3 - Launch 3 new disease registries

Execution Strategy

- Promote case studies to showcase India-specific RWE
- Integrate FHIR–ABDM with OHDSI/OMOP frameworks
- Launch ABDM-compliant disease registries
- Drive academic research and joint publications
- Lead trainings and global OHDSI participation
- Propose joint projects, grants, and disease registries for partnership

INDIA OHDSI
OBSERVATIONAL HEALTH DATA SCIENCES AND INFORMATICS

Thank You

GVW GLOBAL VALUE WEB

JSS ACADEMY OF HIGHER EDUCATION & RESEARCH (DEEMED TO BE UNIVERSITY) MYSURU

OHDSI THAILAND Status Update

@ APAC Community Call June 2025

- **5+ Institutions with OMOP CDM data**
- **3+ Institutions with ongoing studies**
- **7+ Experts showing interests in organizing OHDSI Thailand Chapter** *(coming soon)*
- **Kicking off Monthly Meetup on Next Thursday 26/6 @ 12:30 – 14:00** *(in Thai)*
  - 1st topic on OMOP ETL Pipeline (SQLMesh) at Siriraj Hospital
  - Then, rotating topics on CDM, Vocab, Research, etc.

OHDSI Korea Chapter
Mid-year Update 2025

www.ohdsi-korea.org

Vocabulary Updates in Korea

- **EDI** (Electronic Data Interchange) is a code system of drug, procedure, device and measurement in the Korean national insurance system
- We have **incorporated Korean local EDI vocabularies into OMOP vocabulary**, which is now available on Athena (https://athena.ohdsi.org) with **mappings to standard concepts**
- A detailed **step-by-step tutorial for integrating local vocabulary** into the OMOP CDM has also been published on medRxiv.

Integrating Local Vocabulary into OMOP CDM: A Step-by-Step Tutorial

Posted May 08, 2025.

Yiju Park, Jinwoo Yoon, Aleh Zhuk, Anna Ostropolets, Seng Chan You

doi: https://doi.org/10.1101/2025.05.07.25327200

This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should *not* be used to guide clinical practice.

Abstract | Full Text | Info/History | Metrics

Preview PDF

Download PDF | Print/Save Options | Author Declarations | Supplementary Material | Data/Code

Email | Share | Citation Tools | Get QR code

ABSTRACT

Objectives This tutorial provides healthcare informatics researchers with a practical guide for integrating local vocabularies into the Observational Health Data Sciences and Informatics (OHDSI) Standardized Vocabularies, through the example of Korean Electronic Data Interchange (EDI) codes.

Methods We present a step-by-step guide for integrating local vocabulary. The methodology includes four sequential stages: (1) comprehensive and continuous collection system for longitudinal EDI codes from November 2000 to May 2024, (2) mapping to OHDSI Standardized Vocabularies, (3) validation and integration through the OHDSI Community Contribution Pipeline, and (4) publication into the Athena, the official OHDSI vocabulary site.

Results By following this tutorial, researchers can achieve integration of local vocabulary into the OHDSI Vocabularies. Of the total 620,642 EDI codes collected, we successfully integrated 437,807 codes (70.5%) into the OHDSI Vocabularies, with 376,111 (85.9%) of these integrated codes mapped to standard concepts. The integrated vocabulary passed all Community Contribution Pipeline requirements and was published in September 2024 on the official OHDSI vocabulary website.

Subject Area

Health Informatics

Reviews and Context

0 Comment
0 TRIP Peer Reviews
0 Community Reviews
0 Automated Services
0 Blogs/Media
0 Author Videos

Subject Areas

All Articles

Addiction Medicine
Allergy and Immunology
Anesthesia
Cardiovascular Medicine
Dentistry and Oral Medicine
Dermatology
Emergency Medicine
Endocrinology (including Diabetes Mellitus and Metabolic Disease)
Epidemiology
Forensic Medicine

https://www.medrxiv.org/content/10.1101/2025.05.07.25327200v1

Medical Devices CDM



AI	Product unit	Country code	Company code	Item code	Verification No.	AI	Lot No.	AI	Expiration date	AI	Se
01	0	880	12345	1234	3	10	110500	17	120501	21	9G8

- **Medical Devices WG** is incorporating UDI system for standardized utilization of medical device data
  - **Goal:** Promote data interoperability and advance evidence-based research in medical device area
  - **Unique Device Identifier (UDI):** System for labeling and identifying medical devices within the supply chain from manufacturing

Medical Devices CDM in Korea

In Korea, Medical Device Vigilance CDM (MDV-CDM) R&D project is currently being conducted to establish a comprehensive framework for medical device surveillance

Goal of this project is **to enhance post-market safety surveillance and management of medical devices**

Implementing CDM utilizing both **EDI codes** (de facto Korean standard) and **UDI codes** (international standard)

Medical Devices CDM in Korea

2024

Implementation

- Conversion of 4 new tertiary hospitals
- Including Severance Hospital, Ajou University Hospital

Comparative Analysis

- Knee Prosthesis
- Aortic Valve Implant
- Hemostatic Device

2025

Implementation

- Conversion of 5 new tertiary hospitals
- including Seoul National University Hospital, Korea University Medicine

Comparative Analysis

- LAA Occluder
- Biliary Stent
- Breast Implant

Activation of MDV-CDM



Oncology CDM

- **The Oncology WG** developed the **OMOP Oncology Extension** to integrate the cancer-specific information into the OMOP CDM
  - Cancer disease model
    - Cancer diagnosis: base diagnosis + diagnostic modifiers (e.g. stage, grade, dimension)
  - Cancer treatment model
    - Composite level treatment (regimen) + Individual level (drug exposure)
  - Cancer episode model
    - Patient's journey, including diagnosis, treatment, and outcome



Challenges of EHR for Oncology CDM

- Cancer-specific data is not structured in EHR, making it challenging to standardize to Oncology CDM



Diagnostic modifiers

→ Mostly **unstructured** in clinical notes

Challenges of EHR for Oncology CDM

- Cancer-specific data is not structured in EHR, making it challenging to standardize to Oncology CDM

Example: FOLFOX (Fluorouracil, Leucovorin, Oxaliplatin) up to 6 cycles



Objectives

- Populating OMOP Oncology CDM from the EHR
  - Leverage **generative LLMs** to **structure diagnostic modifiers** from pathology report
  - Aggregate granular **drug exposure** data into **structured regimen** eras
  - Abstract **patients' clinical journeys** into a structured **episode table**

Current Progress in Korea

- We are developing strategy to extract the cancer information from pathology report using state-of-the-art LLM



Current Progress in Korea

- We are aggregating lower-level clinical events to generate Episode table



Source: Adaptation from The Chartis Group, Oncology Solutions

OASIS-CDM

Osteoporosis Analysis and Surveillance Initiative using Standardized data (OASIS)

- The OASIS-CDM in Korea was established in 2023 by **four tertiary care centers** that standardized to version 5.3 of the OMOP-CDM
  - Severance Hospital (6.27 million individuals from January 2006 to August 2023)
  - Asan Medical Center(4.95 million individuals from October 2004 to December 2020)
  - Korea University Anam Hospital (2.18 million individuals from January 2009 to June 2021)
  - Inha University Hospital (1.98 million individuals from February 2001 to February 2019)

OASIS-CDM

- OASIS-CDM provides a collaborative network to **discuss research topics about osteoporosis**, and enables investigations through **real-world, multi-institutional cohort analyses**, ultimately supporting clinical decisions
  - Research topics are discussed through regular monthly meetings
  - The discussion leads to the development of a standardized study protocol and the sharing of analysis codes across institutions

OASIS-CDM

Recent study

- Comprehensive Evaluation of Treatment Patterns in Postmenopausal Patients with Osteoporosis without Fractures: Insights from Tertiary Care Institutions and Nationwide OMOP-CDM Data
  https://github.com/ohdsi-studies/OsteoporosisTreatmentPathways
- Risk of cardiovascular events in osteoporosis patients treated with romosozumab versus denosumab: A multicenter observational cohort study
  https://github.com/dr-you-group/CORDIS

EnM ENDOCRINOLOGY AND METABOLISM
Original Article
Endocrinol Metab 2025 Forthcoming.
https://doi.org/10.3803/EnM.2024.2252
pISSN 2093-596X · eISSN 2093-5978

Comprehensive Evaluation of Treatment Patterns in Postmenopausal Patients with Osteoporosis without Fractures: Insights from Tertiary Care Institutions and Nationwide OMOP-CDM Data

Kyoung Jin Kim[1,*], Dachung Boo[2,3,*], Jimi Choi[1], Hyemin Yoon[4], Chai Young Jung[1], Seong Hee Ahn[5], Namki Hong[3,7], Beom-Jun Kim[8], Ji Seon Oh[4,9], Seng Chan You[2,3]

[1]Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine; [2]Department of Biomedical Systems Informatics, Yonsei University College of Medicine; [3]Institute for Innovation in Digital Healthcare, Yonsei University; [4]Big Data Research Center, Asan Institute of Life Science, Asan Medical Center, Seoul; [5]Biomedical Research Institute, Inha University Hospital; [6]Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha University Hospital, Inha University College of Medicine, Incheon; [7]Department of Internal Medicine, Endocrine Research Institute, Severance Hospital, Yonsei University College of Medicine; [8]Division of Endocrinology & Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine; [9]Department of Information Medicine, Asan Medical Center, Seoul, Korea

Background: Osteoporosis is a global health concern. Despite emerging treatment options for this condition, limited data are available on hospital practices in South Korea. This study addresses the need for a hospital network database that reflects changes in routine clinical practice for osteoporosis in a timely manner.
Methods: We analyzed prescription patterns for anti-osteoporosis medications (AOMs) in postmenopausal women aged ≥50 years diagnosed with osteoporosis between 2012 and 2021 using data from Osteoporosis Analysis and Surveillance Initiative using Standardized data (OASIS) (four tertiary hospitals in South Korea) and a nationwide database from the Health Insurance Review and Assessment (HIRA) Service. AOMs were categorized into antiresorptive and anabolic agents, with a focus on secular changes in the use of oral bisphosphonates, denosumab, selective estrogen receptor modulators (SERMs), and anabolic agents.
Results: In the OASIS cohort, oral bisphosphonates were the most prescribed first-line AOM (49.0%), followed by denosumab (15.7%) and SERMs (18.0%). Denosumab use increased from 2% in 2016 to 40% in 2020, while oral bisphosphonate use declined from 69% in 2012 to 22% in 2021. The use of anabolic agents, including romosozumab and teriparatide, doubled to 6% after 2019. In the HIRA cohort, parenteral bisphosphonates were most common (54.3%), with significant denosumab use (17.3%).

Received: 22 November 2024, **Revised:** 6 January 2025, **Accepted:** 27 February 2025

Corresponding authors: Seng Chan You
Department of Biomedical Systems Informatics, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: +82-2-2228-2500, **Fax:** +82-2-2228-2500, **E-mail:** Chandryou@yuhs.ac

Ji Seon Oh
Department of Information Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea
Tel: +82-2-3010-2530, **Fax:** +82-2-3010-2531, **E-mail:** mdjsoh@amc.seoul.kr

*These authors contributed equally to this work.

Copyright © 2025 Korean
This is an Open Access artic
mons Attribution Non-Cor
licenses/by-nc/4.0/) which
tion, and reproduction in an
cited.



Fig. 2. Trends in anti-osteoporosis medication prescriptions over time. (A) Osteoporosis Analysis and Surveillance Initiative using Standardized data (OASIS) (2012–2021) and (B) Health Insurance Review and Assessment Service (HIRA) (2018–2021) cohort data showing the proportions of postmenopausal women prescribed selective estrogen receptor modulators (SERMs), oral and parenteral bisphosphonates, denosumab, teriparatide, and romosozumab. Prescription trends highlight shifts in medication use over time.



Fig. 3. Anti-osteoporotic treatment pathways for the (A) Osteoporosis Analysis and Surveillance Initiative using Standardized data (OASIS) and (B) Health Insurance Review and Assessment Service (HIRA) cohorts from 2019 to 2021. The sunburst plots display first-line therapies in the center and second- and third-line therapies in the outer rings. Medications include selective estrogen receptor modulators (SERMs), bisphosphonates, denosumab, teriparatide, and romosozumab.

www.ohdsi-korea.org

VIET NAM CHAPTER MID-YEAR UPDATES

PHAN THANH-PHUC, Ph.D.
International Ph.D. program in Biotech and Healthcare Management, TMU
Science and Training Department, UMC

Introducing OHDSI to the community

Mapping vocabulary

Vietnamese Translation of SNOMED-CT



01

Complete First Translation

The initial translation of SNOMED-CT terms is finished.

02

Accuracy Review

Translated concepts are reviewed for accuracy.

03

Consistency Check

The translation is checked for consistency with original semantics.

04

Term Version Control

Version control is established for future updates.

05

Mapping to OMOP

Translated terms are mapped to OMOP standardized vocabularies.

06

Use OHDSI Tools

OHDSI tools are used for validation and management.

UMC CDC Gantt chart



Thank you for your attention!